Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study

  • Caribou Biosciences Inc CRBU announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
  • These initial data will be shared at the European Hematology Association (EHA) 2022 Hybrid Congress.
  • The EHA abstract includes safety, tolerability, and initial antitumor activity of CB-010 administered at dose level 1 (40x106 CAR-T cells) to 6 patients with r/r B-NHL who had relapsed after previous treatment.
  • As of the February 23 data cutoff date, six patients had been treated with CB-010, and five had completed the 28-day dose-limiting toxicity (DLT) evaluation period.
  • 100% (n=5) achieved an overall response rate (ORR), including 80% (n=4) achieved a complete response rate (CR), and 20% (n=1) achieved a partial response (PR). 
  • All four patients who achieved a CR at 28 days had an ongoing CR at 3 months. The longest measured CR as of the data cutoff date was 6 months.
  • Following treatment with CB-010, there was no graft versus host disease cases. 3 of 6 patients developed severe adverse events within the first 28 days: neutropenia (50%), thrombocytopenia (33%), anemia (17%), and hypogammaglobulinemia (17%). 
  • The company is now enrolling patients in cohort 2 of the ANTLER trial at dose level 2 (80x106 CAR-T cells). Additional data are expected by year-end.
  • Price Action: CRBU shares are up 22.20% at $8.10 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!